{"id":"NCT01027949","sponsor":"United Therapeutics","briefTitle":"An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension","officialTitle":"An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01-16","primaryCompletion":"2020-02-12","completion":"2020-02-12","firstPosted":"2009-12-09","resultsPosted":"2021-05-10","lastUpdate":"2021-05-10"},"enrollment":894,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"Oral Treprostinil","otherNames":["Treprostinil diethanolamine, treprostinil diolamine","UT-15C"]}],"arms":[{"label":"Oral Treprostinil","type":"EXPERIMENTAL"}],"summary":"This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308. The study assessed the long term safety of oral treprostinil and the effect of continued treatment with oral treprostinil on exercise capacity after 1 year of treatment.","primaryOutcome":{"measure":"Change in Exercise Capacity at Month 12","timeFrame":"From First Visit (Visit 1) to Month 12","effectByArm":[{"arm":"Oral Treprostinil","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":135,"countries":["United States","Australia","Austria","Belgium","Canada","China","France","Germany","India","Ireland","Israel","Italy","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":547,"n":894},"commonTop":["Headache","Diarrhoea","Nausea","Flushing","Vomiting"]}}